论文部分内容阅读
目的探讨表阿霉素(Epirubicin)联合分子靶向药索拉非尼(Sorafenib)对乳腺癌MCF-7细胞凋亡作用。方法采用人乳腺癌(MCF-7)细胞株。实验分为4组,即对照组、表阿霉素单药组、索拉非尼单药组、索拉非尼+表阿霉素联合组。对各组细胞给予相应药物处理,72h后经流式细胞仪检测各组药物对MCF-7细胞凋亡的作用。结果索拉非尼或表阿霉素单药作用后经流式细胞仪检测,细胞凋亡率均较对照组升高(P<0.05),索拉非尼组诱导的细胞凋亡率为6.34%,表阿霉素组为13.35%。与单药组比,索拉非尼+表阿霉素联合组凋亡率升高更为明显,达23.47%(P<0.05)。结论索拉非尼和表阿霉素的联合应用使抗肿瘤活性显著增强。
Objective To investigate the apoptosis effect of epirubicin combined with molecular targeting agent Sorafenib on breast cancer MCF-7 cells. Methods Human breast cancer (MCF-7) cell line was used. The experiment was divided into 4 groups, namely control group, epirubicin monotherapy group, sorafenib monotherapy group, sorafenib + epirubicin combination group. Each group of cells were given the appropriate drug treatment, 72h after flow cytometry to detect the effect of each group of drugs on MCF-7 cell apoptosis. Results After sorafenib or epirubicin alone was detected by flow cytometry, the apoptotic rate was higher than that of the control group (P <0.05), and the apoptosis rate induced by sorafenib was 6.34 %, Epirubicin group was 13.35%. Compared with single drug group, the apoptosis rate of sorafenib + epirubicin combination group was more obvious, reaching 23.47% (P <0.05). Conclusion Sorafenib and epirubicin combination of anti-tumor activity was significantly enhanced.